Neumora Therapeutics, Inc. Common Stock
NMRANASDAQHealthcare● Active
$1.62
$-0.01(-0.61%)
Market Cap$300160469
P/E Ratio—
52W High$3.65
52W Low$0.716
Neumora Therapeutics, Inc. Common Stock (NMRA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NMRA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.01B) | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.18B | $0.20B | $0.14B | $0.10B | $0.21B |
| G&A Expenses | $0.06B | $0.06B | $0.05B | $0.03B | $0.02B |
| Total Operating Expenses | $0.24B | $0.26B | $0.19B | $0.14B | $0.24B |
| Operating Income | ($0.24B) | ($0.26B) | ($0.19B) | ($0.14B) | ($0.24B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.02B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.24B) | ($0.24B) | ($0.24B) | ($0.13B) | ($0.24B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.24B) | ($0.24B) | ($0.24B) | ($0.13B) | ($0.24B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.45 | $-1.53 | $-1.49 | $-0.86 | $-1.56 |
| Wtd Avg Shares | 0.16B | 0.16B | 0.16B | 0.15B | 0.15B |
| EBITDA | ($0.23B) | ($0.26B) | ($0.19B) | ($0.14B) | ($0.24B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Neumora Therapeutics, Inc. Common Stock data
About Neumora Therapeutics, Inc. Common Stock (NMRA) Income Statement
Neumora Therapeutics, Inc. Common Stock (NMRA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NMRA reported revenue of $0.00B, gross profit of ($0.01B) (gross margin —), and net income of ($0.24B) — a net profit margin of —.
Frequently asked questions
NMRA · 4 questionsNeumora Therapeutics, Inc. Common Stock (NMRA) reported revenue of $0.00B for 2025, down —% year-over-year.
NMRA revenueNMRA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08